Haemonetics (HAE) Earnings Date & Reports

Key Takeaways

• Haemonetics Corporation (HAE) is scheduled to report first quarter fiscal 2027 results on Thursday, August 6, 2026, before the U.S. market opens, with a conference call to follow at 8:00 a.m. ET.
• Wall Street consensus estimates project adjusted earnings per share (EPS) of approximately $1.09 and revenue near $328 million, representing a modest year-over-year decline in EPS from the $1.10 reported in Q1 fiscal 2026.
• The report arrives on the heels of a strong Q4 fiscal 2026, during which Haemonetics delivered $1.29 in adjusted EPS on $346.4 million in revenue, surpassing analyst expectations and completing its four-year portfolio transformation plan.
• Analyst sentiment is broadly constructive but divided — Mizuho and Bank of America have issued bullish calls, while Citi recently placed the stock on a "downside 90-day catalyst watch," citing elevated expectations.
• Investors will zero in on the performance of the Plasma franchise, the trajectory of the Interventional Technologies (IVT) recovery, and whether management reaffirms or adjusts its fiscal 2027 full-year guidance.

Earnings Context and Why It Matters

Haemonetics enters its fiscal 2027 reporting cycle at a pivotal juncture. The company recently completed an ambitious four-year transformation that streamlined its portfolio, exited low-margin businesses, and repositioned the organization around higher-growth platforms in plasma collection, blood management, and vascular closure. The Q4 fiscal 2026 results validated that strategy — organic revenue growth, excluding the impact of the CSL contract transition, reached 9%, and adjusted operating margins expanded to 25.4% for the full year. Now, with the turnaround phase formally behind it, the Q1 fiscal 2027 report represents the first clean read on whether Haemonetics can sustain mid-single-digit organic growth and margin expansion without the tailwind of transformation-related catch-up effects. For investors, this quarter sets the tone for the year ahead.

Earnings Expectations

Consensus estimates for the first quarter of fiscal 2027 point to adjusted EPS of roughly $1.09, with a range of $1.03 to $1.14 across covering analysts. Revenue expectations center around $328 million, which would represent a modest increase from the $321.4 million posted in the same period a year ago. These estimates reflect an anticipated normalization following the strong finish to fiscal 2026.

For the full fiscal year 2027, Haemonetics management has guided to reported revenue growth of 4% to 7% (3% to 6% on an organic basis, adjusted for foreign exchange and an extra 53rd week), adjusted operating margin expansion of 50 to 100 basis points, and adjusted EPS growth broadly in line with reported revenue. Free cash flow conversion is targeted at approximately 80%, down from the 89% achieved in fiscal 2026, reflecting ongoing investment in commercial infrastructure and the integration of the Vivasure acquisition.

At the segment level, the Plasma business is expected to deliver mid-single-digit growth, supported by share gains, the rollout of the Persona PLUS technology, and steady global immunoglobulin demand. The Hospital segment, which includes both Blood Management Technologies (such as the TEG 6s coagulation analyzer) and Interventional Technologies (vascular closure devices), is also guided to mid-single-digit growth. The Blood Center segment, however, is projected to decline mid-single digits as Haemonetics continues to optimize its portfolio away from lower-margin product lines.

Haemonetics has a strong track record of topping consensus. In each of the four quarters of fiscal 2026, the company exceeded both EPS and revenue estimates. The Q1 fiscal 2026 report delivered an EPS beat of roughly 9% ($1.10 actual versus $1.01 consensus), setting a high bar for the upcoming release.

AI Screener

Tracking earnings season across the medical technology landscape can be time-consuming, but tools like Tickeron's AI Screener are designed to simplify the process. The AI Screener is an AI-powered stock and ETF discovery tool that allows traders and investors to filter thousands of securities using customizable criteria — including industry, market capitalization, technical indicators, price patterns, volatility metrics, and AI-driven signals. Rather than manually scanning through charts and financial statements, users can quickly surface trade ideas, identify breakout candidates, and spot trending stocks aligned with their strategies. For those monitoring the medtech sector ahead of Haemonetics' report, the screener offers an efficient way to compare peer performance and uncover related opportunities.

Market Reaction and Investor Sentiment

Haemonetics shares have rallied sharply heading into this earnings release, gaining approximately 35% since late March 2026 and recently trading near $80. The stock has benefited from the strong Q4 fiscal 2026 report, multiple analyst upgrades — including Bank of America's upgrade to Buy and Mizuho's price target increase to $90 — and the company's inclusion in several Russell indexes. The consensus analyst rating stands at Buy, with an average 12-month price target of approximately $86.60.

However, the elevated valuation and strong run-up have introduced a higher bar for the Q1 print. The stock currently trades at a forward price-to-earnings (P/E) ratio above 15 times fiscal 2027 estimates, a significant re-rating from earlier in the year. Citi's decision to add a "downside 90-day catalyst watch" in early July — while simultaneously raising its price target — underscores the tension: Haemonetics may beat and raise, but that outcome may already be partially priced in. Short interest stands at roughly 6.8% of the float, and any disappointment on guidance or key segment metrics could trigger volatility.

Forward Outlook and Key Factors to Monitor

Beyond the headline numbers, several factors will shape how investors interpret the Q1 fiscal 2027 results and what they signal for the remainder of the year.

First, the Plasma segment's organic growth rate will be closely scrutinized. Haemonetics has consistently gained share in U.S. plasma collections, and the recent FDA clearance of the NexSys PCS with Persona PLUS technology — which improves plasma yield by a mid-single-digit percentage — provides a new catalyst. Analysts will want to hear about early adoption trends and whether the technology is accelerating customer conversions.

Second, the Interventional Technologies recovery remains a critical swing factor. IVT revenue declined 9% in fiscal 2026, weighed down by share losses in electrophysiology and headwinds from the adoption of pulsed field ablation (PFA), a newer catheter-based procedure for treating atrial fibrillation. Management has indicated that the largest headwinds are now behind the business, with the VASCADE MVP XL label expansion and the anticipated PerQseal Elite launch representing potential growth accelerators. Any evidence of sequential improvement in vascular closure volumes would be well received.

Third, margin trajectory and cost management will be in focus. Fiscal 2027 guidance embeds a higher assumed tariff rate (15% versus approximately 10% currently), ERP (enterprise resource planning) system implementation costs, and a full year of dilution from the Vivasure acquisition. Investors will look for signs that gross margin expansion — driven by a richer product mix and operating leverage — is progressing as planned.

Finally, any commentary on capital allocation will matter. Haemonetics ended fiscal 2026 with $245 million in cash and generated $210 million in free cash flow. The company deployed $175 million toward share repurchases and $61 million for the Vivasure acquisition. With the transformation phase complete, the balance sheet capacity for additional buybacks or bolt-on mergers and acquisitions (M&A) remains a topic of interest.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations